Related Experiment Video

Updated: Nov 26, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.3K

Leuko-platelet index predicts thrombotic events in patients with acute coronary syndrome

Hernán Cohen Arazi1, Daniel Chirino2, Juan Pablo Costabel3

  • 1Argentine Society of Cardiology, Buenos Aires, Argentina.

International Journal of Cardiology
|December 10, 2020
PubMed

Insights

The leuko-platelet index (LPI) can predict adverse outcomes in acute coronary syndromes (ACS) patients. An LPI greater than 24 is linked to higher mortality and resistance to antiplatelet therapy.

Area of Science:

  • Cardiology
  • Biomarkers
  • Clinical Prediction

Background:

  • Acute coronary syndromes (ACS) are a leading cause of cardiovascular mortality.
  • Accurate risk stratification and prediction of treatment response are crucial for managing ACS patients.
  • Novel biomarkers are needed to improve bedside risk assessment.

Purpose of the Study:

  • To evaluate the predictive value of the leuko-platelet index (LPI) in hospitalized patients with ACS.
  • To assess the association of LPI with the risk of combined adverse events (mortality, shock, heart failure) and response to antiplatelet therapy.

Main Methods:

  • A derivation cohort of 1100 ACS patients was used to establish the association between LPI and clinical outcomes.
  • LPI was calculated as (platelet count * leukocyte count / 10^8).
  • Validation was performed in two independent cohorts.

Main Results:

  • LPI was significantly higher in patients with myocardial infarction compared to unstable angina.
  • An LPI > 24 was associated with an increased risk of combined adverse events (OR 1.7-5.2, p=0.01), independent of age and GRACE score.
  • Elevated LPI was also linked to resistance to antiplatelet therapy (OR 1.03, p=0.05).

Conclusions:

  • The leuko-platelet index (LPI) is a valuable bedside index for predicting adverse outcomes in ACS patients.
  • An LPI > 24 identifies patients at higher risk for mortality, shock, or heart failure.
  • LPI may also predict resistance to antiplatelet therapy, guiding treatment decisions.
Abstract

Keywords:
CoronaryIndexLeukocytesPlateletsPrognosisSyndrome

More Related Videos

Real-time Imaging of Heterotypic Platelet-neutrophil Interactions on the Activated Endothelium During Vascular Inflammation and Thrombus Formation in Live Mice11:18

Real-time Imaging of Heterotypic Platelet-neutrophil Interactions on the Activated Endothelium During Vascular Inflammation and Thrombus Formation in Live Mice

Published on: April 2, 2013

16.0K
Intravital Microscopy of Leukocyte-endothelial and Platelet-leukocyte Interactions in Mesenterial Veins in Mice05:12

Intravital Microscopy of Leukocyte-endothelial and Platelet-leukocyte Interactions in Mesenterial Veins in Mice

Published on: August 13, 2015

12.8K

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
97
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
878
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
227